Finance

Lists
Outlook: 61.5% bullish·0.0% bearish
Go to analysis
CAH:NYSE
Cardinal Health, Inc
USD 232,57
-0,33%
(-0,76) 1D
7 Okt., 12:59:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CAH...
Open
USD 233,61
High
USD 235,97
Low
USD 232,49
Mkt. cap
53,85 mjd
Avg. vol.
1,74 m
Volume
290,38 k
Dividend
0,89%
Quarterly dividend
USD 0,52
Ex-dividend date
01 Okt. 2026
P/E ratio
32,16
52-wk high
USD 258,30
52-wk low
USD 151,87
EPS
USD 7,23
Beta
0,50
Shares outstanding
231,56 m
No. of employees
61 k
Open
USD 233,61
High
USD 235,97
Low
USD 232,49
Mkt. cap
53,85 mjd
Avg. vol.
1,74 m
Volume
290,38 k
Dividend
0,89%
Quarterly dividend
USD 0,52
Ex-dividend date
01 Okt. 2026
P/E ratio
32,16
52-wk high
USD 258,30
52-wk low
USD 151,87
EPS
USD 7,23
Beta
0,50
Shares outstanding
231,56 m
No. of employees
61 k
News stories
From web sources and news partners
Profile
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States. Wikipedia
About Cardinal Health, Inc
CEOJason Hollar
Employees61,3 k
Founded1971
HeadquartersDublin, Ohio, Verenigde State van Amerika
SectorHealth care provider
Analyst ratings
Based on 14 analysts giving stock ratings to CAH in the past 3 months
Strong buy
Buy
12
Hold
2
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for CAH in the last 3 months.
Highest
Current USD 232,57
USD 292,00 (+25,55%)
Average
USD 270,00 (+16,09%)
Lowest
USD 250,00 (+7,49%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ryan Halsted
RBC Capital
Buy
Maintained
USD 276,00
+18,7%
10/06/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
USD 277,00
+19,1%
09/09/2026
Glen Santangelo
Barclays
Buy
Reiterated
USD 275,00
+18,2%
08/18/2026
Lisa Gill
J.P. Morgan
Hold
Maintained
USD 260,00
+11,8%
08/17/2026
George Hill
Deutsche Bank
Hold
Maintained
USD 261,00
+12,2%
08/13/2026
Steven Valiquette
Mizuho Securities
Buy
Maintained
USD 250,00
+7,5%
08/13/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
USD 280,00
+20,4%
08/13/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
USD 270,00
+16,1%
08/12/2026
Erin Wright
Morgan Stanley
Buy
Maintained
USD 255,00
+9,6%
08/12/2026
Daniel Grosslight
Citi
Buy
Maintained
USD 280,00
+20,4%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
USD 277,00
+19,1%
08/12/2026
Michael Cherny
Leerink Partners
Buy
Maintained
USD 292,00
+25,6%
08/11/2026
Ryan Daniels
William Blair
Buy
Reiterated
-
-
08/11/2026
Allen Lutz
Bank of America Securities
Buy
Maintained
USD 260,00
+11,8%
07/20/2026
Kevin Caliendo
UBS
Buy
Reiterated
USD 274,00
+17,8%
07/20/2026
Unknown Analyst
William O'Neil
Buy
Initiated
-
-
06/12/2026
Unknown Analyst
Argus Research
Buy
Maintained
USD 248,00
+6,6%
05/05/2026
Steven Silver
Argus Research
Buy
Maintained
USD 248,00
+6,6%
05/05/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
USD 248,00
+6,6%
05/01/2026
Max Smock
William Blair
Buy
Initiated
-
-
04/28/2026
Last report
11 Aug. 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
USD 2,60 / USD 2,42
+7,41%beat
Revenue / Est. (USD)
63,67 mjd / 65,11 mjd
-2,20%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
64,01 mjd
65,63 mjd
60,94 mjd
63,67 mjd
Cost of goods sold
61,69 mjd
63,23 mjd
58,44 mjd
61,11 mjd
Cost of revenue
61,69 mjd
63,23 mjd
58,44 mjd
61,11 mjd
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,46 mjd
1,50 mjd
1,54 mjd
1,62 mjd
Operating expense
1,55 mjd
1,59 mjd
1,64 mjd
1,71 mjd
Total operating expenses
63,24 mjd
64,82 mjd
60,08 mjd
62,82 mjd
Operating income
771,00 m
809,00 m
861,00 m
847,00 m
Other non operating income
10,00 m
11,00 m
-16,00 m
30,00 m
EBT including unusual items
598,00 m
630,00 m
392,00 m
554,00 m
EBT excluding unusual items
701,00 m
732,00 m
744,00 m
794,00 m
Income tax expense
144,00 m
159,00 m
12,00 m
154,00 m
Effective tax rate
24,08%
25,24%
3,06%
27,80%
Other operating expenses
-
-
-
-
Net income
450,00 m
467,00 m
399,00 m
398,00 m
Net profit margin
0,70%
0,71%
0,65%
0,62%
Earnings per share
2,55
2,63
3,17
2,60
Interest and investment income
-
-
-
-
Interest expense
-80,00 m
-88,00 m
-101,00 m
-103,00 m
Net interest expenses
-80,00 m
-88,00 m
-101,00 m
-103,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,00 mjd
1,04 mjd
1,11 mjd
1,09 mjd
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme